Luxturna is a one-time treatment for children and adults who have suffered impaired vision from an early age due to mutations in both copies of the RPE65 gene.
Novartis gets European approval for sight therapy Luxturna
More from Industry NewsMore posts in Industry News »
- Aurobindo, Unichem recall products in US market
- After recommending booster dose for 40+, INSACOG says more experiments needed
- Omicron scare: Experts advise booster doses for health workers
- BioNTech CEO confident of quickly adapting vaccine for Omicron
- Double vaccinate against Covid first, experts say amid calls for booster shots